Department of Biochemistry, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.
Graduate School of Biotechnology, Universitas Andalas, Padang, Indonesia.
J Complement Integr Med. 2022 Apr 25;19(3):619-626. doi: 10.1515/jcim-2021-0549. eCollection 2022 Sep 1.
Gestational diabetes (GDM) complications affect maternal and fetus . GDM's vascular dysfunction showed inducible nitric oxide synthase (iNOS) alteration and was linked to the higher production of nitrogen species, leading to diabetic embryopathy. () has been reported for its anti-inflammatory and anti-diabetic effects. Thus, the present study investigates the anti-diabetic effect, lipid-lowering effect, and iNOS expression in GDM animal models treated with extract.
Four groups of pregnant rats consist of control and GDM groups. One GDM group was set for control positive. Two GDM groups were treated with extract in two doses (100 and 200 mg/kg BW) for 14 days. Blood glucose of all groups was observed at 72 h after STZ injection and 14 days after administration of extract. Lipid profile and iNOS expression using real-time PCR were measured afterward.
extract lowered blood glucose levels in both doses, from 262.60 mg/dL±6.89-136.80 mg/dL ± 15.6 mg/dL and 113.20 mg/dL±5.25 mg/dL. Total cholesterol, LDL and triglyceride showed a reduction, especially in 200 mg/kg BW dose extract from 122.37 mg/dL ± 14.84 mg/dL, 69.75 mg/dL±3.78 mg/dL and 137.51 mg/dL ± 8.12-74.64 mg/dL±8.71 mg/dL, 40.26 mg/dL±3.31 mg/dL and 87.57 mg/dL±6.29 mg/dL, respectively. iNOS expression downregulated in both doses, from 2.17±0.39 to 0.94±0.3 and 0.41±0.08.
This study showed that extract has a potential therapeutic activity in lowering blood glucose, improved lipid profile, and downregulating iNOS in GDM.
妊娠糖尿病（GDM）并发症会影响母婴。GDM 的血管功能障碍表现为诱导型一氧化氮合酶（iNOS）改变，并与氮物种的产生增加有关，导致糖尿病胚胎病。（）已被报道具有抗炎和抗糖尿病作用。因此，本研究调查了在 GDM 动物模型中用提取物治疗的抗糖尿病作用、降血脂作用和 iNOS 表达。
四组怀孕大鼠包括对照组和 GDM 组。一个 GDM 组设为对照组。两个 GDM 组分别用提取物以两种剂量（100 和 200 mg/kg BW）治疗 14 天。所有组在 STZ 注射后 72 小时和给予提取物后 14 天观察血糖。随后测量血脂谱和 iNOS 表达的实时 PCR。
提取物降低了两个剂量的血糖水平，从 262.60mg/dL±6.89-136.80mg/dL±15.6mg/dL 和 113.20mg/dL±5.25mg/dL。总胆固醇、LDL 和甘油三酯均有所下降，特别是 200mg/kg BW 剂量提取物从 122.37mg/dL±14.84mg/dL、69.75mg/dL±3.78mg/dL 和 137.51mg/dL±8.12-74.64mg/dL±8.71mg/dL、40.26mg/dL±3.31mg/dL 和 87.57mg/dL±6.29mg/dL。两种剂量的 iNOS 表达均下调，从 2.17±0.39 降至 0.94±0.3 和 0.41±0.08。
本研究表明，提取物在降低血糖、改善血脂谱和下调 GDM 中的 iNOS 方面具有潜在的治疗活性。
